Evaluating the cost of medications for ambulatory HIV-infected persons in association with landmark changes in antiretroviral therapy

Article Abstract:

The cost and complexity of drug treatment for HIV infection likely increased from June 1995, when guidelines to prevent opportunistic infections in HIV were published, to September 1996. Researchers at a university-based primary care clinic calculated the average wholesale cost of all medications for HIV patients. During the study period, monthly medication costs rose from an average of $477 to $1,048 per patient. Patients with the most severe disease had the highest medication costs. Increased costs primarily resulted from greater use of antiretroviral drugs and combination drug therapy regimens.

Analysis, Economic aspects, Medical care, Cost of, Health care costs, Antiviral agents, Drug therapy, Combination, Combination drug therapy

---

Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy

Article Abstract:

New AIDS drugs are needed to eradicate the virus that hides out inside cells. Aggressive therapy can suppress the virus in the bloodstream, but residual virus still exists inside cells. Researchers measured this residual virus inside the blood cells of 10 HIV patients who were on aggressive drug therapy and had undetectable blood levels of HIV. After one year of treatment, the level of HIV inside the blood cells had decreased, but it was always detectable.

Physiological aspects, HIV (Viruses), HIV

---

Similar abstracts:

• Abstracts: Clinical research and drug development of antivirals in HIV: an industry perspective. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection
• Abstracts: Nutritional influences on growth and prevalence of anemia in children during the war in Sarajevo. Birthweight and breast feeding of babies born during the war in one municipal area of Sarajevo
• Abstracts: Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial. part 2

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.